MRG-001 in Patients With Alcoholic Hepatitis

Alcoholic Hepatitis Clinical Trial

Official title:

An Open-Label, Dose-Escalation Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of MRG-001 in Patients With Alcoholic Hepatitis

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06307522
• Other study ID #: MRG24ALC
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: September 1, 2024
• Est. completion date: December 1, 2026

Study information

• Verified date: March 2024
• Source: MedRegen LLC
• Contact: Ali R Ahmadi, MD PhD
• Phone: 4437598563
• Email: info[@]medregenco.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this study is to test MRG-001 (an experimental medication). The purpose of this trial is to assess the dose related safety, Pharmacokinetics, and Pharmacodynamics of MRG-001 in patients with severe alcoholic hepatitis (AH).

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 32
• Est. completion date: December 1, 2026
• Est. primary completion date: September 1, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 21 Years and older

Eligibility

Inclusion Criteria:

1. Informed Consent: Able to provide written informed consent, either personally or through a legally acceptable representative.

2. Male or female patients 21 years of age or older.

3. Onset of jaundice within the prior 8 weeks.

4. Alcohol Consumption: Average daily consumption of more than 40 grams for females or more than 60 grams for males of alcohol for 6 months or longer, with less than 8 weeks of abstinence before the onset of jaundice.

5. Diagnostic Criteria for AH: AH may be diagnosed based on typical serum chemistry or liver biopsy during the current episode of AH, including:

• Serum bilirubin > 3 mg/dL

• AST between 50 and 400 IU/L

• ALT < 400 IU/L

• AST/ALT ratio > 1.5

6. Maddrey Discriminant Function (MDF): MDF = 32, assuming a control prothrombin time of 12 seconds.

7. Model for End-stage Liver Disease (MELD) Score: MELD score between 21 and 30.

8. Liver Biopsy (Optional): Liver biopsy is not required but may be used to confirm the diagnosis of AH at the Investigator's discretion. If used, the biopsy must have occurred during the current episode.

9. Contraception for Women: Women of childbearing potential must use appropriate birth control throughout the study duration. Contraception for Men: Male patients must agree to use a medically acceptable method of contraception or birth control throughout the study duration.

Exclusion Criteria:

1. Informed Consent: Inability to provide written informed consent, either personally or through a legally acceptable representative.

2. Participation in Other Clinical Trials: Participation in another interventional clinical trial (drug or device) within 30 days of screening and at any time during the study.

3. Concomitant Liver Diseases: Presence of other concomitant causes of liver disease, such as viral hepatitis, autoimmune liver disease, metabolic liver disease, or vascular liver disease.

4. Liver Biopsy Incompatibility: Liver biopsy findings, if conducted, not compatible with alcoholic hepatitis (AH).

5. Absence of Active Infection: No evidence of active infection as determined by the investigator, with specific criteria outlined for diagnosing and treating infections.

6. Uncontrolled Gastrointestinal Bleeding: Presence of uncontrolled gastrointestinal bleeding.

7. History of pre-admission refractory ascites, as defined by the frequency of paracenteses despite diuretic therapy.

8. Significant pre-existing organ dysfunction in various systems, including lung, heart, kidney, hematologic, neurological, and spleen-related conditions.

1. Lung: Receiving supplemental home oxygen therapy at baseline for pre-existing medical condition (other than COVID-19), as documented in medical record.

2. Heart: Pre-existing congestive heart failure defined as an ejection fraction <20% as documented in the medical record. Clinically significant ventricular arrhythmias (ventricular tachycardia, ventricular fibrillation), unstable angina, myocardial infarction (past 3 months), heart and coronary vessel surgery (past 3 months), significant valvular heart disease, uncontrolled arterial hypertension with systolic blood pressure >180 mm Hg and diastolic blood pressure >110 mm Hg.

3. Renal: End-stage renal disease requiring renal replacement therapy or creatintine clearance <30 mL/min.

4. Hematologic: Baseline platelet count <30,000/mm3 or hemoglobin levels <6.0 g/dL.

5. Neurological: Stage =3 hepatic encephalopathy by West Haven criteria.

6. History of splenectomy or splenomegaly (spleen weighing > 750 g).

9. Presence of any active malignancy or malignancy diagnosed within the last five years, excluding curable skin cancer.

10. Patients requiring the use of vasopressors or inotropic support, excluding stabilized conditions within the first 7 days of hospital admission.

11. Presence of co-infection with human immunodeficiency virus (HIV) or active tuberculosis on chest X-ray at study entry.

12. History of organ or bone marrow transplantation, excluding corneal transplant, or recent chronic use of immunosuppressive drugs.

13. Positive urine drug screen for specific substances, excluding THC and prescription medications.

14. Hypersensitivity to either of the components of MRG-001.

15. If female, known pregnancy, positive serum pregnancy test, or lactating/breastfeeding.

16. Underlying diseases that might be complicated or exacerbated by proposed treatments or confound assessment of study drug, as determined by the site investigator.

Related Conditions & MeSH terms

• Acute Alcoholic Hepatitis
• Alcoholic Hepatitis
• Hepatitis
• Hepatitis A
• Hepatitis, Alcoholic

Intervention

Drug:
• MRG-001
Patients will receive subcutaneous administration of MRG-001 at designated visits.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
MedRegen LLC

References & Publications (1)

Ahmadi AR, Atiee G, Chapman B, Reynolds L, Sun J, Cameron AM, Wesson RN, Burdick JF, Sun Z. A phase I, first-in-human study to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics of MRG-001 in healthy subjects. Cell Rep Med. 2023 — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Assessment of Treatment-Emergent Adverse Events	Assess the safety and tolerability of MRG-001 in patients with alcoholic hepatitis (AH) as determined by the absence of suspected unexpected serious adverse reaction (SUSAR).	28 Days
Secondary	Pharmacokinetic Response	Determine the pharmacokinetics (PK) of MRG-001 in patients with AH. Trough levels (Ctrough) of plerixafor and tacrolimus will be measured throughout the study.	28 Days
Secondary	Pharmacodynamic Response	The PD response will be measured by flow cytometry. The absolute number of CD34+ hematopoietic stem cells in the peripheral circulation will be assessed and compared to baseline levels.	28 Days

External Links

•   Company Profile